- $455.45m
- $464.79m
- $233.80m
Cerus Corp reports results for the quarter ended in March - Earnings Summary
Brief: Cerus Corp Announces Q1 2021 Financial Results And Raises Full Year Product Revenue Guidance
Cerus Corp expected to post a loss of 9 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Life Storage, Pactiv Evergreen
Brief: Cerus Corp Reports Q4 Loss Per Share Of $0.09
Brief: Cerus Corp, Shandong Zhongbaokang Medical Implements Partner To Establish Joint Venture In China
Brief: Cerus Corp Announces Preliminary Q4 And Full Year 2020 Product Revenue
Brief: Cerus Enters Amendment To Certain Credit, Security And Guaranty Agreement
Brief: Cerus Files For Offering Of $100 Mln Of Common Stock - SEC Filing
Brief: Cerus Announces Presentation Of Study Results With Intercept-Treated COVID-19 Convalescent Plasma At The American Society Of Hematology Annual Meeting
U.S. RESEARCH ROUNDUP- Appian, Biogen, IHS Markit
Cerus: Up on FDA nod for additional use of blood purification device
Brief: Cerus Corporation Announces FDA Approval For INTERCEPT Blood System for Cryoprecipitation
Brief: Cerus Corporation Announces Record Third Quarter 2020 Results
Brief: Cerus Announces Five-Year FDA Contract For Development Of Next Generation Pathogen Reduction Technology To Treat Whole Blood
U.S. RESEARCH ROUNDUP- Accelerate Diagnostics, Honeywell, Neophotonics
Brief: Cerus Intercept Blood System Kit Shipments Surpass 7.5 Mln Treatable Platelet And Plasma Doses
Brief: Cerus Q2 Revenue $26.8 Million Versus Refinitiv Ibes Estimate Of $25.9 Million
Brief: Cerus Announces Five-Year Tender Award By Hong Kong Red Cross Blood Transfusion Service